About Biocon Biologics
Biocon Biologics is a global biosimilars company making complex, high-quality medicines accessible to patients worldwide. Their Semglee (insulin glargine), Kixelle (trastuzumab biosimilar), Fulphila (pegfilgrastim) and Abevmy (bevacizumab) are approved by the USFDA, EMA and WHO. With manufacturing in India and Malaysia, Biocon serves patients in more than 120 countries.
📍 Location & Offices
📋 Request a Quote
Send your requirements directly to Biocon Biologics. Response typically within 48 hours.
Company Info
TypePublic
StockBIOCON (BSE/NSE)
Founded2001
Employees7,000
Revenue$900M
HQBengaluru, India